Last updated: August 27, 2026
Vaxchora, the only FDA-approved live oral cholera vaccine in the United States, has a specialized commercial position rather than a mass-market vaccine profile. Bavarian Nordic markets the product primarily to international travelers, military personnel, humanitarian workers, and others entering areas with active cholera transmission. Demand recovered after the COVID-19 travel shutdowns, but revenue remains exposed to travel volumes, outbreak activity, public-health procurement, and competition from lower-cost killed oral cholera vaccines.
Bavarian Nordic does not publicly report Vaxchora revenue as a separate line item. Its financial trajectory must therefore be assessed through the company’s Travel Health portfolio, product availability, travel recovery, and cholera-vaccine procurement trends. The product has meaningful regulatory and manufacturing barriers, but its narrow indication and limited addressable market constrain blockbuster potential.
What is the commercial status of Vaxchora?
Vaxchora is a live, attenuated, single-dose oral vaccine containing recombinant Vibrio cholerae serogroup O1, strain CVD 103-HgR. The vaccine is administered before travel to areas where cholera transmission is active.
The product was developed by PaxVax and acquired by Bavarian Nordic when Bavarian Nordic purchased PaxVax in 2018. It is marketed in the United States and forms part of Bavarian Nordic’s Travel Health business alongside products such as RabAvert, Rabipur, and other travel-related vaccines.
| Attribute |
Vaxchora |
| Active component |
Live attenuated recombinant V. cholerae O1 |
| Dosage form |
Oral suspension prepared from powder |
| Primary use |
Travel-related cholera prevention |
| U.S. regulatory status |
FDA-approved biologic |
| U.S. approval |
2016 |
| Administration |
Single oral dose |
| Commercial owner |
Bavarian Nordic A/S |
| Original developer |
PaxVax |
| Main customer groups |
Travelers, military, humanitarian and occupational-risk populations |
| U.S. mass vaccination role |
Limited |
| Publicly disclosed product-specific revenue |
Not separately reported |
The product is not positioned as a routine vaccine for the general U.S. population. CDC guidance targets travelers entering areas with active cholera transmission, especially where access to safe food, water, and medical care is limited.[1]
How large is the cholera vaccine market?
The global cholera vaccine market is divided into two structurally different segments:
- International travel and occupational vaccination.
- Public-health stockpiling and outbreak-response campaigns.
Vaxchora is strongest in the first segment. The second segment is dominated by killed oral cholera vaccines supplied through international procurement channels, including Shanchol and Euvichol-Plus.
Travel market
The commercial travel market depends on:
- International passenger volumes.
- Travel-health clinic activity.
- Military deployments.
- Humanitarian missions.
- Government travel advisories.
- Cholera outbreaks in destination countries.
- Insurance and employer reimbursement.
- Vaccine availability before departure.
Travel-health demand fell sharply during 2020 and 2021. The reopening of international travel produced a recovery in 2022 and 2023, with continued support from higher travel volumes and infectious-disease preparedness. The recovery was uneven by region because travel clinics, pharmacy networks, and government purchasing contracts reopened at different rates.
Vaxchora benefits from its single-dose oral administration and FDA approval. Its commercial disadvantage is the limited number of travelers for whom cholera vaccination is recommended.
Public-health market
The public-health segment is larger in population terms but less accessible to Vaxchora. WHO-prequalified killed oral cholera vaccines are used for preventive campaigns and emergency response, generally through Gavi, UNICEF, ministries of health, and other public-health agencies.[2]
Vaxchora’s U.S. FDA approval does not automatically provide WHO prequalification. Without a major public-health procurement position, the product is less likely to capture large international vaccination campaigns. Its live-vaccine platform, cold-chain requirements, dosing logistics, and higher expected acquisition cost relative to public-sector oral vaccines also limit its competitiveness in mass campaigns.
What is the financial trajectory for Vaxchora?
Vaxchora’s financial trajectory has four phases.
| Period |
Market condition |
Likely effect on Vaxchora |
| 2016-2019 |
Product launch and travel-market development |
Gradual commercial buildout |
| 2020-2021 |
International travel collapse |
Severe demand contraction |
| 2022-2023 |
Travel reopening and clinic normalization |
Strong recovery from depressed base |
| 2024 onward |
Normalized travel with outbreak-driven variability |
Moderate growth potential, volatile annual demand |
Bavarian Nordic reports financial performance by broader business areas and does not disclose Vaxchora sales separately in its public annual reporting. The company’s Travel Health revenue includes multiple products, which prevents a reliable standalone revenue or margin calculation for Vaxchora.[3]
Revenue drivers
Vaxchora revenue is most sensitive to:
- U.S. outbound travel.
- Product availability at travel clinics and pharmacies.
- Cholera prevalence in destination markets.
- CDC and government travel recommendations.
- Military and government contracts.
- Distributor inventory levels.
- Competition from oral and injectable alternatives.
- Bavarian Nordic’s manufacturing capacity and allocation decisions.
The product can produce higher revenue per vaccinated person than public-sector cholera vaccines because it is sold through private travel-health channels. That price advantage is offset by a small eligible population and demand that can be deferred when travel declines.
Margin profile
Vaxchora’s cost structure likely includes:
- Specialized live-biologic manufacturing.
- Potency and identity testing.
- Freeze-dried drug product production.
- Packaging and administration instructions.
- Cold-chain distribution.
- Regulatory maintenance across jurisdictions.
- Inventory management for a product with episodic demand.
A single-dose vaccine can have favorable administration economics in private clinics, but product profitability depends heavily on manufacturing utilization and inventory turnover. A low-volume biologic can carry a high fixed-cost burden even when the per-dose price is attractive.
How does Vaxchora compare with Dukoral, Shanchol, and Euvichol-Plus?
Vaxchora has a distinct profile compared with killed oral cholera vaccines.
| Product |
Vaccine type |
Main market |
Dosing profile |
Key commercial position |
| Vaxchora |
Live attenuated |
U.S. and international travelers |
Single dose |
FDA-approved travel vaccine |
| Dukoral |
Killed whole-cell with recombinant B subunit |
Travelers and some public-health use |
Multi-dose |
Broad international availability |
| Shanchol |
Killed whole-cell |
Public-health campaigns |
Multi-dose |
WHO-prequalified mass-campaign product |
| Euvichol-Plus |
Killed whole-cell |
Public-health campaigns |
Multi-dose |
Large humanitarian and government procurement role |
Dukoral is a direct travel-market competitor in several countries. Shanchol and Euvichol-Plus compete mainly for public-health procurement rather than U.S. retail travel demand.
Vaxchora’s main differentiator is the single-dose live oral regimen. Its limitations include narrower geographic commercial penetration, a live-organism safety profile, and lower relevance to mass vaccination programs.
What is the FDA regulatory status of Vaxchora?
Vaxchora is licensed under a biologics license application rather than approved as a conventional small-molecule drug. FDA approval was granted in 2016 for adults ages 18 through 64 traveling to areas of active cholera transmission. FDA later expanded the indicated population to include children aged 2 years and older.[4]
The label includes restrictions associated with live bacterial vaccines. Vaxchora is not intended for treatment of cholera. Vaccination does not replace food and water precautions, and protection against non-O1 serogroups or other causes of diarrhea is not established.
FDA exclusivity
The principal FDA exclusivity period associated with the original approval has expired. The original product approval dates from 2016, and the product is no longer in the period typically associated with a newly approved biologic’s initial market exclusivity.
Later pediatric or labeling supplements may have received separate regulatory protections, but those protections do not create a new product-wide exclusivity period equivalent to the original approval. The FDA’s Purple Book and regulatory records are more relevant than the Orange Book for assessing Vaxchora’s biologic approval status.[5]
What is the Orange Book status of Vaxchora?
Vaxchora is generally not evaluated through the standard Orange Book patent-listing framework used for small-molecule drugs. It is a licensed biologic vaccine, so the relevant regulatory reference is the FDA Purple Book and the underlying biologics license application.
This distinction affects generic-entry analysis:
- A conventional ANDA pathway is not the normal route for a live biologic vaccine.
- A biosimilar pathway is theoretically relevant to biologics but is commercially and technically difficult for a live attenuated vaccine.
- FDA approval of a competing vaccine would normally require an independent clinical and manufacturing program rather than a simple generic substitution.
- Pharmacy-level automatic substitution is not expected to operate like substitution for a conventional small-molecule drug.
What patents protect the live oral cholera vaccine?
The original CVD 103-HgR technology was developed before Bavarian Nordic acquired PaxVax. Core platform patents covering the attenuated strain, genetic construction, or vaccine composition are likely to have substantial age and may be expired or approaching expiration, depending on the specific jurisdiction, patent family, priority date, and patent-term adjustments.
Current commercial protection is more likely to depend on:
- Manufacturing know-how.
- Cell banking and seed-lot controls.
- Fermentation and stabilization processes.
- Lyophilization parameters.
- Formulation and reconstitution instructions.
- Quality-control assays.
- Regulatory exclusivity.
- Trade secrets and operational scale.
No reliable product-specific patent expiry date should be assigned without a verified patent-family review tied to the current Vaxchora formulation and manufacturing process. Publicly available product information does not establish a single enforceable patent expiry date that would determine competitive entry.
How strong is the patent estate for Vaxchora?
The patent estate appears less important than the regulatory and manufacturing barriers.
| Protection category |
Relative importance |
| Original strain or platform patents |
Potentially weakened by age |
| Product-composition patents |
Depends on claim scope and remaining term |
| Formulation patents |
Could protect stability or presentation |
| Manufacturing patents |
Potentially valuable if difficult to design around |
| Trade secrets |
High relevance for live-biologic production |
| FDA biologic exclusivity |
Original period largely elapsed |
| Clinical and regulatory package |
Important practical barrier |
| Brand and distribution |
Material in travel-health channels |
The strongest competitive moat is likely the combination of regulatory approval, validated manufacturing, product availability, and channel relationships rather than a single blocking patent.
Are there Paragraph IV challenges or generic-entry risks?
There is no conventional Paragraph IV pathway for Vaxchora comparable to the ANDA process used for small-molecule drugs. A competitor cannot generally rely on an abbreviated generic application to enter the market by challenging Orange Book-listed patents.
The main entry scenarios are:
- A competitor develops and licenses another oral cholera vaccine.
- A biologic competitor pursues a biosimilar or interchangeable product, although the technical fit is uncertain.
- A manufacturer obtains approval for a killed oral vaccine in the same travel market.
- A public-health supplier expands into private travel vaccination.
- A regional competitor uses a separate regulatory pathway outside the United States.
The practical risk of near-term U.S. generic substitution is low. The larger risk is competitive displacement by another approved cholera vaccine with a lower price, broader international availability, easier supply, or stronger public-health procurement support.
What formulation and manufacturing barriers protect Vaxchora?
Vaxchora is supplied as a lyophilized formulation that must be reconstituted before oral administration. Live bacterial vaccines require controls over:
- Attenuated-strain identity.
- Genetic stability.
- Viability and potency.
- Contamination.
- Fermentation conditions.
- Freeze-drying performance.
- Storage and transport.
- Reconstitution timing.
- Batch consistency.
These requirements create a higher entry barrier than a conventional oral tablet. A competitor must demonstrate not only clinical protection but also stable manufacturing of a live organism at commercial scale.
Manufacturing failure, supply interruption, or inventory expiry can have an outsized effect on financial performance because the addressable market is relatively small and demand is episodic.
Which companies are challenging Vaxchora?
Competition is fragmented rather than concentrated around a single U.S. challenger.
Bavarian Nordic
Bavarian Nordic controls Vaxchora and has the strongest U.S. regulatory and commercial position for a live oral cholera vaccine. Its broader vaccine portfolio provides sales infrastructure, but the company does not disclose Vaxchora-specific revenue.
Valneva and Dukoral-related suppliers
Dukoral is an established killed oral cholera vaccine used in international travel markets. Its multi-dose regimen differs from Vaxchora, but it remains the principal commercial comparator in travel vaccination.
EuBiologics
EuBiologics supplies Euvichol-Plus for global public-health campaigns. The company is a major participant in the international cholera-vaccine supply chain, although its principal competition with Vaxchora is in procurement and policy rather than U.S. retail substitution.
Shantha Biotechnics and related supply channels
Shanchol has been used in international outbreak-response and preventive campaigns. Its public-sector positioning gives it access to demand pools that are structurally different from Vaxchora’s travel market.
What patent litigation and settlement agreements affect Vaxchora?
No major publicly disclosed U.S. patent litigation or Paragraph IV settlement appears to define Vaxchora’s current commercial outlook. The principal legal issues are more likely to concern biologic licensing, manufacturing rights, supply arrangements, regulatory compliance, and international intellectual-property rights than ANDA patent litigation.
Bavarian Nordic’s acquisition of PaxVax transferred commercial and development assets, including Vaxchora-related rights, into Bavarian Nordic’s portfolio. Acquisition-related licensing and supply terms are not equivalent to a generic settlement and should not be treated as evidence of impending generic entry.[6]
What geographic markets are available for Vaxchora?
Vaxchora’s economic value is highest in markets with:
- High outbound international travel.
- Established travel-medicine clinics.
- Private vaccine reimbursement.
- Regulatory acceptance of the product.
- Cholera risk among travelers.
- Reliable distribution and cold-chain infrastructure.
The United States is the central commercial market because of FDA approval and CDC travel guidance. International expansion depends on country-specific approvals and reimbursement. In lower-income countries, the product competes against public-health vaccines purchased through pooled procurement, making premium private-market pricing difficult to sustain.
What generic launch scenarios exist for Vaxchora?
Base case
Vaxchora maintains its U.S. travel-vaccine position, with revenue tracking international travel and occasional cholera-risk spikes. Growth is moderate and uneven.
Downside case
A competing vaccine gains approval, Vaxchora experiences supply constraints, or travel-health clinics shift toward lower-cost alternatives. Revenue falls despite stable overall cholera-vaccine demand.
Upside case
A major cholera outbreak increases travel vaccination, military demand, humanitarian deployment, or government stockpiling. Expanded pediatric use and wider international approvals improve volume, although outbreak-driven demand may not persist.
Low-probability disruption case
A new vaccine achieves WHO prequalification while also securing strong private travel distribution. That product could pressure Vaxchora in both procurement and travel markets.
How exposed is Bavarian Nordic to Vaxchora revenue?
Vaxchora is strategically relevant but unlikely to be a major standalone driver of Bavarian Nordic’s consolidated financial profile. Bavarian Nordic’s revenue base includes larger vaccine franchises and government-related contracts, particularly for travel vaccines, rabies vaccines, and preparedness products.[3]
Because Vaxchora-specific sales are not separately disclosed, investors should monitor:
- Travel Health segment revenue.
- Product-supply commentary.
- Gross-margin movement.
- Manufacturing utilization.
- Inventory provisions.
- U.S. travel-clinic ordering.
- Regulatory approvals outside the United States.
- Cholera outbreak activity.
- Government procurement announcements.
The product is more valuable as a differentiated addition to a broader travel-health portfolio than as an independent blockbuster asset.
Key Takeaways
- Vaxchora is the leading U.S. live oral cholera vaccine and is owned by Bavarian Nordic.
- Its commercial market is concentrated in international travelers, military personnel, and humanitarian workers.
- Public-health cholera campaigns are dominated by killed oral vaccines such as Shanchol and Euvichol-Plus.
- Product-specific revenue is not disclosed, so financial performance must be inferred from Bavarian Nordic’s broader Travel Health reporting.
- The post-pandemic travel recovery supported demand from 2022 onward.
- Original FDA exclusivity has largely elapsed, but generic substitution is limited because Vaxchora is a biologic vaccine.
- No conventional Paragraph IV challenge is expected to determine market entry.
- Manufacturing know-how, live-organism controls, regulatory approval, and distribution are more important barriers than a single identifiable blocking patent.
- Near-term upside depends on travel recovery, pediatric demand, outbreak activity, and international expansion.
- The main commercial risk is not a conventional generic. It is a competing oral cholera vaccine with lower cost, broader procurement access, or better supply.
FAQs
Is Vaxchora a live vaccine or a killed vaccine?
Vaxchora is a live, attenuated oral vaccine based on recombinant V. cholerae O1 strain CVD 103-HgR.
Can Vaxchora be used for routine cholera vaccination in the United States?
No. U.S. use is primarily directed at people traveling to areas with active cholera transmission and elevated exposure risk.
Does Vaxchora have an Orange Book patent listing?
Vaxchora is a biologic vaccine, so the FDA Purple Book and biologics regulatory records are more relevant than the conventional Orange Book framework.
Is Vaxchora interchangeable with Dukoral?
No. The products differ in vaccine composition, dosing, regulatory approvals, and market availability. They should not be treated as automatic substitutes.
What is the biggest long-term risk to Vaxchora sales?
The largest risk is competition from another approved cholera vaccine with lower pricing, broader international distribution, stronger public-health procurement access, or more reliable supply.
References
-
Centers for Disease Control and Prevention. (2024). Cholera vaccine: Recommendations for travelers. CDC Travelers’ Health.
-
World Health Organization. (2023). Cholera vaccines: Position paper. World Health Organization.
-
Bavarian Nordic A/S. (2024). Annual report 2023. Bavarian Nordic.
-
U.S. Food and Drug Administration. (2020). FDA approves expanded use of Vaxchora for children. FDA.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
-
Bavarian Nordic A/S. (2018). Bavarian Nordic completes acquisition of PaxVax. Bavarian Nordic.
